Opioid Use Disorder Drugs Market to Grow with a CAGR of 9.67% through 2028
Expanding adoption of Medication-Assisted Treatment
(MAT) programs are expected to drive the Global Opioid Use Disorder Drugs Market
growth in the forecast period, 2024-2028.
According to TechSci Research report, “Opioid Use
Disorder Drugs Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Opioid Use Disorder Drugs Market
stood at USD 2.45 billion in 2022 and is anticipated to grow with a CAGR of 7.65%
in the forecast period, 2024-2028. The Global Opioid Use Disorder (OUD) Drugs Market is
witnessing unprecedented growth driven by a convergence of factors that
collectively address one of the most pressing public health crises of our time:
opioid addiction. With opioid misuse and overdose-related deaths reaching
alarming proportions worldwide, the demand for effective treatments is higher
than ever before. The primary driver fueling the growth of the Global
OUD Drugs Market is the escalating opioid epidemic. Opioid addiction has become
a global crisis, with millions of individuals struggling with dependence on
prescription opioids or illicit drugs like heroin. The sheer scale of this
epidemic has led to increased recognition of the need for comprehensive
treatment solutions, thereby driving the demand for OUD drugs. Heightened
public awareness and education campaigns have played a pivotal role in boosting
the OUD Drugs Market. Governments, non-profit organizations, and healthcare
providers have been working tirelessly to educate the public about the risks
associated with opioids and the availability of effective treatments. As
individuals become more informed about OUD and its treatment options, the demand
for OUD drugs has increased.
Governments across the globe have recognized the
severity of the opioid crisis and have responded with substantial funding and
policy support. These initiatives include expanding access to OUD medications,
reducing stigma associated with addiction, and improving healthcare
infrastructure for addiction treatment. The financial support provided by
governments has significantly expanded the OUD Drugs Market. The development of
innovative and effective treatment options has been a major driver of market
growth. OUD drugs can be categorized into three main classes: opioid agonists,
partial agonists, and antagonists. New medications with improved efficacy and
safety profiles continue to emerge. For example, extended-release formulations
of buprenorphine, such as Sublocade and Probuphine, offer long-lasting relief
from withdrawal symptoms, reducing the burden on patients to take daily
medications. Research and development efforts within the pharmaceutical
industry are dedicated to creating better and more accessible OUD drugs. These
efforts are focused on developing new formulations, improving drug delivery
mechanisms, and investigating novel medications. As science advances and
understanding of addiction deepens, the market benefits from the development of
more potent and targeted drugs.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Opioid Use Disorder Drugs Market.”
The COVID-19 pandemic accelerated the adoption of
telemedicine and telehealth services, which has positively impacted the OUD
Drugs Market. Telehealth has made it easier for individuals with OUD to access
healthcare professionals and receive prescriptions for necessary medications
remotely. This increased accessibility has improved treatment adherence and
outcomes. Reducing the stigma associated with addiction and addiction treatment
has been a key driver for market growth. As societal attitudes evolve, more
individuals are seeking help for OUD without fear of judgment or
discrimination. The reduction of stigma has resulted in more people seeking
treatment, thereby driving demand for OUD drugs.Furthermore, the integration of
digital health technologies and telemedicine has expanded access to treatment
and improved patient outcomes. Telehealth services have made it easier for
individuals with OUD to connect with healthcare providers, receive
prescriptions, and access counseling and support remotely. This has enhanced
the overall treatment experience and increased the reach of OUD medications.
The Global Opioid Use Disorder Drugs Market is
segmented into derived drug type, route of administration, end user, regional
distribution, and company.
Based on type, the Global Opioid Use Disorder Drugs Market
is segmented into Agonist Drugs, Antagonist Drugs, Others. Based on the
drug Type, the agonist drugs segment emerged as the dominant player in the
global market for Global Opioid Use Disorder Drugs Market in 2022. This is on
account of their ability to effectively address opioid addiction by targeting
the same receptors in the brain that opioids do, thereby reducing cravings and
withdrawal symptoms. Additionally, opioid agonists have a
track record of success in helping individuals achieve and maintain abstinence
from illicit opioids like heroin. Their use in Medication-Assisted Treatment
(MAT) programs, often combined with counseling and behavioral therapies, has
been associated with improved treatment outcomes and long-term recovery. Furthermore,
the increasing recognition of the opioid epidemic as a public health crisis has
led to more comprehensive policies and initiatives aimed at expanding access to
opioid agonist drugs. Governments and healthcare organizations are promoting
the integration of MAT into mainstream addiction treatment, reducing regulatory
barriers, and increasing funding to support these programs.
Based on Application, the Global Opioid Use Disorder
Drugs Market is segmented into Oral, Parenteral, Sublingual, Nasal. Based on the
Route of Administration, the Oral segment emerged as the dominant player in the
global market for Global Opioid Use Disorder Drugs Market in 2022. Oral medications are generally easy
to administer and do not require specialized medical procedures or equipment.
Patients can take their medication at home or in a clinical setting, enhancing
convenience and accessibility. Oral medications are often preferred by patients
due to their familiarity and ease of use. This can contribute to better
adherence to treatment regimens, as patients are more likely to take their
medications consistently. Taking oral medications is less stigmatizing than
other routes of administration, such as intravenous (IV) or intranasal (nasal)
administration. Reduced stigma can encourage more individuals to seek OUD
treatment.
Oral OUD medications, such as methadone and
buprenorphine, are formulated to have a slower onset of action and a longer
duration, reducing the risk of overdose compared to rapidly acting routes like
intravenous injection.
North America emerged as the dominant player in the
global Opioid Use Disorder Drugs market in 2022, holding the largest market
share. North America, particularly the United States, has been severely
impacted by the opioid epidemic, with a high prevalence of OUD. This epidemic
has driven the demand for OUD medications and treatment services in the region.
Government Initiatives and Funding: Governments in North America have
recognized the urgency of addressing the opioid crisis and have taken proactive
measures. They have implemented policies and allocated significant funding to
expand access to OUD treatment, including Medication-Assisted Treatment (MAT)
programs.
Major companies operating in Global Opioid Use
Disorder Drugs Market are:
- Mallinckrodt Pharmaceuticals
- Hikma Pharmaceuticals Inc
- Collegium Pharmaceutical, Inc.
- Braeburn, Inc.
- Purdue Pharma L.P.
- Curia Global Inc.
- EMERGENT
- Bristol-Myers Squibb, S.r.l
- Alkermes, Inc.
- Indivior Inc
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The global
Opioid Use Disorder (OUD) Drugs Market is anticipated to experience substantial
growth and evolution in the coming years. The persistent opioid epidemic, coupled
with changing healthcare dynamics, will be instrumental in shaping the market's
future. The key trends and factors driving this market include the increasing
recognition of addiction as a public health priority, which is likely to lead
to continued investment in OUD treatment research and development. Additionally,
the expansion of Medication-Assisted Treatment (MAT) programs, which combine
pharmacotherapy with counseling and behavioral therapies, is expected to drive
demand for OUD medications. Telehealth and digital solutions are set to play a
pivotal role in improving treatment accessibility, especially in remote or
underserved areas. The market may witness advancements in OUD medication
formulations and drug delivery methods, enhancing patient convenience and
adherence.” said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based management consulting firm.
“Global Opioid Use Disorder Drugs Market - Global Industry Size, Share, Trends, Opportunity,
and Forecast, 2018-2028 Segmented By Drug Type (Agonist Drugs, Antagonist
Drugs, Others), By Route of Administration (Oral, Parenteral, Sublingual,
Nasal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online
Pharmacies) By Region and Competition”, has evaluated the future growth potential of Global
Opioid Use Disorder Drugs Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Opioid
Use Disorder Drugs Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel:
+1-646-360-1656
Email:
[email protected]
Website:
www.techsciresearch.com